

## EQA round: BIL1/25 - Bilirubin Neonatal

Deadline: 21.3.2025

Setup: groups - M (measurement principle); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D <sub>max</sub> = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	CVPG = consensus of the participants' groups	UL = upper limit
N <sub>tot</sub> = total number of the results	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	N <sub>eva</sub> = number of the results assessed
N <sub>out</sub> = number of the results removed before calculation		N <sub>suc</sub> = number of successful results
		S <sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability								
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]	
<b>(215) Bilirubin total</b>	[μmol/L]				18							18	18	100	
<b>Sample A</b>		141	7	5	18		CVP	140	2,6	18%	114	166	18	18	100
(2) DCA, DPD		140	7,6	5,4	15	0							15		
Other					3	0							3		
							1x 1, 1x 5, 1x 7								
<b>Sample B</b>		272	13	4,6	18		CVP	272	5,2	18%	223	321	18	18	100
(2) DCA, DPD		270	14	5,4	15	0							15		
Other					3	0							3		
							1x 1, 1x 5, 1x 7								
<b>(216) Bilirubin direct</b>	[μmol/L]				16								16	16	100
<b>Sample A</b>		33,3	7,6	23	16								16	16	100
(2) DCA, DPD; (58) Beckman Coulter (AU)		37,4	2,1	5,5	11	0	CVPG	37,9	1,1	18%	31	44,8	11		
Other					5	0							5		
							1x 2/1, 3x 2/60, 1x 7/179								
<b>Sample B</b>		53,5	9,6	18	16								16	16	100
(2) DCA, DPD; (58) Beckman Coulter (AU)		58,3	3,2	5,4	11	0	CVPG	59,5	1,6	18%	48,7	70,3	11		
Other					5	0							5		
							1x 2/1, 3x 2/60, 1x 7/179								